Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer’s disease ; volume:11 ; number:1 ; day:18 ; month:7 ; year:2019 ; pages:1-9 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (18.7.2019), 1-9, 12.2019
- Urheber
-
den Haan, Jurre
Csinscik, Lajos
Parker, Tom
Paterson, Ross W.
Slattery, Catherine F.
Foulkes, Alexander
Bouwman, Femke H.
Verbraak, Frank D.
Scheltens, Philip
Peto, Tunde
Lengyel, Imre
Schott, Jonathan M.
Crutch, Sebastian J.
Shakespeare, Timothy J.
Yong, Keir X. X.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-019-0516-x
- URN
-
urn:nbn:de:101:1-2019122219062320544847
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- den Haan, Jurre
- Csinscik, Lajos
- Parker, Tom
- Paterson, Ross W.
- Slattery, Catherine F.
- Foulkes, Alexander
- Bouwman, Femke H.
- Verbraak, Frank D.
- Scheltens, Philip
- Peto, Tunde
- Lengyel, Imre
- Schott, Jonathan M.
- Crutch, Sebastian J.
- Shakespeare, Timothy J.
- Yong, Keir X. X.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population
Accelerating regional atrophy rates in the progression from normal aging to Alzheimer’s disease
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future
The “rights” of precision drug development for Alzheimer’s disease
Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury
The plasma peptides of Alzheimer’s disease
Eyes-closed task-free electroencephalography in clinical trials for Alzheimer’s disease: an emerging method based upon brain dynamics
Reproducibility of EEG functional connectivity in Alzheimer’s disease
Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
Sensitive and reproducible MEG resting-state metrics of functional connectivity in Alzheimer’s disease
Practical use of visual medial temporal lobe atrophy cut-off scores in Alzheimer’s disease: Validation in a large memory clinic population